Effect of green coffee supplementation on androgens level in women with polycystic ovary syndrome: A Randomized Clinical Trial
Abstract
Abstract The present study was aimed at determining the effect of green coffee supplementation on androgens level in women with Poly-Cystic Ovary Syndrome (PCOS) through double-blind Randomized Clinical Trial (RCT). Each patient (n = 17) in the treatment group received one green coffee capsule (400 mg) and the control group (n = 17) received one placebo for six weeks. Then, the levels of free testosterone, dihydrotestosterone, and androstenedione; lipid profile; glycemia and insulinemia indices; and anthropometric indices before and after the intervention were determined and compared. The results showed green coffee supplements reduced testosterone level (P = 0.038). There was no significant difference in general characteristics of the participants, including education, occupational status, age of illness, and metformin usage. At the beginning and the end of the study, there was a significant decrease in triglyceride (P = 0.007) and total cholesterol level (P = 0.035) in the green coffee group in comparison with the placebo group. However, no significant difference in anthropometric data including weight, Body Mass Index (BMI), waist circumference, and waist-to-hip ratio was observed. Moreover, no significant difference was observed in fasting blood glucose, insulin levels, insulin resistance index, LDL, HDL, dihydrotestosterone, and androstenedione. The results of the clinical trial showed that supplementation of 400 mg green coffee a day for six weeks significantly reduced…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 17 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.